Efficacy and Safety of valproate use in the Patients With newly dignosis glioblastoma

Efficacy and Safety of valproate in the Patients With newly dignosis glioblastoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005004

Enrollment

Unknown

Registered

2014-07-23

Start date

2014-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma

Interventions

A:VPA with RT/TMZ-TMZ

B:RT/TMZ-TMZ

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed intracranial glioblastoma; 2. Karnofsky performance status of 60 or more; 3. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits; 4. At least 18 years old; 5. Both men and women must practice adequate contraception; 6. Informed consent.

Exclusion criteria

Exclusion criteria: Evidence of acute intracranial or intratumoral hemorrhage worse than Grade 1, Pregnant or breast feeding, Uncontrolled intercurrent illness, Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study, HIV positive, Diagnosis of another malignancy may exclude subject from study.

Design outcomes

Primary

Measure	Time frame
perioperative seizure happend rates;late seizure happend rates;overall survival;progression-free survival;quality of life;side effect of VPA;	—

Contacts

Public ContactMao Qing

qingmao2000@163.com+86 18980601806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026